Jumei F. Shi - Publications

Targeting endosomal trafficking-mediated antigen escape to resensitize myeloma to CAR-T therapy.

Journal: Journal for immunotherapy of cancer

Published: February 15, 2026

Corrigendum to "Dihydrocelastrol induces cell death and suppresses angiogenesis through BCR/AP-1/junb signalling in diffuse large B cell lymphoma" [Arch. Biochem. Biophys. 754 (2024) 109929].

Journal: Archives of biochemistry and biophysics

Published: October 29, 2025

A systematic review on the clinical characteristics and treatment outcomes of accelerated silicosis

Journal: Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases

Published: July 01, 2025

Editor's Note: A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.

Journal: Cancer research

Published: June 27, 2025

METTL16 enhances proteasome inhibitor resistance in multiple myeloma by inhibiting eIF2α-PERK interaction and promoting PSMB5 translation.

Journal: Oncogene

Published: June 23, 2025

Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay.

Journal: RSC medicinal chemistry

Published: December 18, 2024

Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease.

Journal: Cancer pathogenesis and therapy

Published: September 02, 2024

Aberrant activation of adenine nucleotide translocase 3 promotes progression and chemoresistance in multiple myeloma dependent on PINK1 transport.

Journal: International journal of biological sciences

Published: August 03, 2024

Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real-world study in China.

Journal: American journal of hematology

Published: July 10, 2024

Corrigendum to "Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells" [Int. Immunopharmacol. 125(Part A) (2023) 111139].

Journal: International immunopharmacology

Published: June 22, 2024

EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma.

Journal: Acta biochimica et biophysica Sinica

Published: May 28, 2024

Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis.

Journal: Journal of biomedical science

Published: May 05, 2024